Hyperglycemia News and Research

RSS
Hyperglycemia occurs when you have a higher than usual level of glucose in your blood. This can happen shortly after you have eaten a big meal and is not a problem if your glucose level returns to normal. Cells remove glucose from the blood in response toinsulin. If your pancreas doesn't make enough insulin, glucose can't enter the cells and remains in the blood. Blood glucose levels can also get too high if cells areunable to respond to insulin properly (insulinresistance). Without glucose, your cells are unable to make energy and can't function properly.
Afinitor more than doubles progression-free survival in advanced pancreatic NET: Study

Afinitor more than doubles progression-free survival in advanced pancreatic NET: Study

Eisai reports preliminary results from Dacogen for Injection Phase III study in AML

Eisai reports preliminary results from Dacogen for Injection Phase III study in AML

SuperGen encouraged by Eisai's intent to file Dacogen sNDA for new indication

SuperGen encouraged by Eisai's intent to file Dacogen sNDA for new indication

Rosiglitazone therapy associated with increased risk for heart attack: Study

Rosiglitazone therapy associated with increased risk for heart attack: Study

Lantus and Apidra improve outcomes, decrease glycemic variability: Study

Lantus and Apidra improve outcomes, decrease glycemic variability: Study

Dapagliflozin in addition to insulin improves glycemic control in type 2 diabetics

Dapagliflozin in addition to insulin improves glycemic control in type 2 diabetics

AFREZZA provides long-term glucose control in Type 2 diabetics: Study

AFREZZA provides long-term glucose control in Type 2 diabetics: Study

Halozyme presents new data from Ultrafast Insulin development program at 70th ADA

Halozyme presents new data from Ultrafast Insulin development program at 70th ADA

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

Lantus and Apidra injections improve glycemic control, reduce hospital complications: Study

Lantus and Apidra injections improve glycemic control, reduce hospital complications: Study

Japan's MHLW grants full marketing authorization to REVLIMID

Japan's MHLW grants full marketing authorization to REVLIMID

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

Cellonis' stem cells diabetes treatment helps reconstruct natural insulin production

Cellonis' stem cells diabetes treatment helps reconstruct natural insulin production

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Dapagliflozin as monotherapy demonstrates potential for type 2 diabetes treatment

Dapagliflozin as monotherapy demonstrates potential for type 2 diabetes treatment

A review of the response to oral anti-diabetes agents in patients with type 2 diabetes

A review of the response to oral anti-diabetes agents in patients with type 2 diabetes

How to obtain appropriate type 2 diabetes control in the first 180 days of treatment initiation

How to obtain appropriate type 2 diabetes control in the first 180 days of treatment initiation

Diabetes associated with increased risk of cancer

Diabetes associated with increased risk of cancer

UOHI tests Canada's first in-hospital program to screen and treat patients for diabetes

UOHI tests Canada's first in-hospital program to screen and treat patients for diabetes

Phase III study of REVLIMID for treating patients with multiple myeloma shows improvement in PFS

Phase III study of REVLIMID for treating patients with multiple myeloma shows improvement in PFS

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.